Testing inebilizumab for children with IgG4-related disease
Treatments studied
Part of Immune system & allergy clinical trials.
This trial tests if inebilizumab is safe and works well for children with IgG4-related disease (a condition causing swelling in various organs). It may be an option if your child needs treatment beyond steroids.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Weigh at least 17 kg (about 37.5 pounds)
- Age 2 to under 18 years old
- Diagnosed with IgG4-related disease involving certain organs (like pancreas, bile ducts, eyes, lungs, kidneys, or glands)
- Need treatment beyond or in addition to steroids
- Be up to date on age-appropriate vaccinations before the study
- Not have certain serious infections, low blood counts, or recent use of specific immune-suppressing drugs
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a medication called rilzabrutinib to see if it can safely control IgG4-related disease (a condition causing inflammation in various organs) better than a placebo. It may help you reduce or stop your current steroid treatment.
This study looks at a specific immune signal (C5a/C5aR1) in IgG4-related disease to see if blocking that signal could be a future treatment. It compares blood samples from people with active disease, people in remission, and healthy volunteers.
This trial tests if lenalidomide, taken as a pill, can help prevent IgG4-related disease from coming back (relapsing) in people who are already in remission on low-dose steroids.
This study tests if an investigational drug called inebilizumab is safe and helpful for children with generalized myasthenia gravis (gMG). It is for children ages 2 to 17 who have certain antibodies or typical symptoms of gMG and are already on stable treatment.
This is a study that follows people diagnosed with IgG4-related disease to better understand the condition. It may help researchers confirm diagnoses and learn how the disease affects different organs over time.
This trial tests a new medicine called IMM0306 for IgG4-related disease, a condition where the immune system attacks multiple organs in your body. The study aims to see if IMM0306 can help control your disease and reduce flare-ups while using less steroid medication.
Hear when a new Immunoglobulin G4-Related Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.